$328 Million is the total value of Opaleye Management Inc.'s 43 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | EPIZYME INC | $17,131,000 | +1.3% | 1,365,000 | 0.0% | 5.22% | +11.5% | |
| QURE | UNIQURE NV | $16,021,000 | +31.0% | 205,000 | 0.0% | 4.88% | +44.2% | |
| AMRN | AMARIN CORP PLCsponsored adr | $12,507,000 | -6.6% | 645,000 | 0.0% | 3.81% | +2.8% | |
| BOLD | AUDENTES THERAPEUTICS INC | $10,601,000 | -3.0% | 280,000 | 0.0% | 3.23% | +6.8% | |
| XOMA | XOMA CORP DEL | $5,944,000 | +20.0% | 400,000 | 0.0% | 1.81% | +32.2% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $5,346,000 | -0.4% | 200,000 | 0.0% | 1.63% | +9.5% | |
| BLRX | BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019)sponsored adr | $91,000 | -15.7% | 250,000 | 0.0% | 0.03% | -6.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 42 | Q2 2024 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 30 | Q2 2024 | 3.6% |
| OCULAR THERAPEUTIX INC | 27 | Q2 2024 | 17.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| ETON PHARMACEUTICALS INC | 23 | Q2 2024 | 5.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| TG THERAPEUTICS INC | 20 | Q2 2024 | 10.1% |
| CRINETICS PHARMACEUTICALS INC | 20 | Q1 2024 | 5.6% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iBio, Inc. | April 09, 2024 | 650,000 | 7.6% |
| OCULAR THERAPEUTIX, INC | February 14, 2024 | 6,070,000 | 5.5% |
| SANUWAVE Health, Inc. | February 14, 2024 | 115,493,554 | 9.1% |
| HARROW, INC. | February 09, 2024 | 3,820,000 | 10.9% |
| Jounce Therapeutics, Inc.Sold out | February 09, 2024 | 0 | 0.0% |
| Tracon Pharmaceuticals, Inc. | February 09, 2024 | 10 | 0.0% |
| Context Therapeutics Inc. | January 05, 2024 | 820,000 | 5.1% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-23 |
| 4 | 2024-09-19 |
| SC 13G/A | 2024-09-18 |
| 3 | 2024-09-12 |
| 4 | 2024-09-12 |
| 4 | 2024-09-12 |
| SC 13G/A | 2024-09-12 |
| 4 | 2024-09-10 |
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.